Product Description
Reference Standards &Impurity
AI Product Description
*The following content is generated by AI and is for reference only.
Fenofibrate is a widely prescribed synthetic lipid-lowering agent belonging to the fibrate class of drugs. Chemically, its molecular formula is C20H21ClO4, and it carries the unique CAS Registry Number 7685-57-4. This compound functions primarily as an agonist for peroxisome proliferator-activated receptor alpha (PPAR-α), a nuclear transcription factor that regulates genes involved in lipid metabolism. By activating PPAR-α, fenofibrate significantly enhances the activity of lipoprotein lipase, leading to accelerated catabolism of triglyceride-rich particles such as very-low-density lipoproteins (VLDL) and chylomicrons. Consequently, it effectively lowers serum triglyceride levels by up to 50% in many patients.
Beyond its potent triglyceride-reducing capabilities, fenofibrate offers additional cardiovascular benefits. It modestly increases high-density lipoprotein cholesterol (HDL-C), often referred to as "good" cholesterol, while simultaneously reducing low-density lipoprotein cholesterol (LDL-C) levels. The drug is indicated for the treatment of severe hypertriglyceridemia, mixed dyslipidemia, and primary hypercholesterolemia, particularly when dietary modifications and lifestyle changes prove insufficient. Clinical studies suggest that fenofibrate may also reduce the risk of pancreatitis in patients with extremely high triglyceride concentrations. Furthermore, emerging evidence points to potential anti-inflammatory properties, which could contribute to vascular protection. Fenofibrate is available in various formulations, including immediate-release tablets, micronized capsules, and extended-release versions, allowing for flexible dosing strategies tailored to individual patient needs. Common side effects are generally mild but may include gastrointestinal discomfort, headache, or elevated liver enzymes. Regular monitoring of renal function and liver enzymes is recommended during long-term therapy to ensure safety and efficacy. As a cornerstone in managing complex lipid disorders, fenofibrate remains a vital tool in preventing cardiovascular events associated with dyslipidemia.